GlassScriptPhysician profile
Aneta Stirling
NPI 1952527541
$15,632.80
in general payments reported to CMS, 2019-2025
40 companies · $1,719 in 2025
The $1,719 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,094 · 2020: $1,863 · 2021: $2,150 · 2022: $3,210 · 2023: $1,938 · 2024: $1,659 · 2025: $1,719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,315.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,354.82 | 2019-2025 | Repatha, Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $1,605.84 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $1,530.40 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $1,176.62 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $993.55 | 2019-2024 | Jardiance, Tradjenta, Synjardy |
| Abbvie INC. | $922.87 | 2020-2025 | Ubrelvy, Synthroid, Linzess |
| Janssen Pharmaceuticals, INC | $857.04 | 2019-2024 | Xarelto |
| Allergan, INC. | $561.48 | 2019-2020 | |
| Pfizer INC. | $534.31 | 2019-2025 | |
| Lilly USA, LLC | $496.83 | 2019-2025 | Mounjaro, Emgality, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $489.71 | 2022-2024 | |
| Therapeuticsmd, INC. | $476.51 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $405.59 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $372.32 | 2019-2022 | |
| Daiichi Sankyo INC. | $360.94 | 2021-2023 | Injectafer |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $305.43 | 2019-2024 | Rybelsus, Ozempic |
| Alexion Pharmaceuticals, INC. | $280.81 | 2024-2025 | Ultomiris |
| Esperion Therapeutics, INC. | $251.93 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $216.26 | 2020-2023 | Verquvo, Steglatro, Belsomra |
| Abbott Laboratories | $205.18 | 2024-2025 | Freestyle Libre 3, Proclaim |
| Biohaven Pharmaceuticals, INC. | $148.63 | 2021 | |
| Mylan Specialty L.P. | $137.56 | 2019 | |
| Sanofi Pasteur INC. | $130.45 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.08 | 2020-2021 | |
| Eisai INC. | $97.76 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.27 | 2019-2025 | Xifaxan |
| Astellas Pharma US INC | $63.76 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $59.35 | 2020-2021 | |
| Almatica Pharma LLC | $59.10 | 2021-2024 | Loreev Xr |
| Seqirus USA INC | $56.40 | 2022-2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| E.R. Squibb & Sons, L.L.C. | $56.28 | 2019-2022 | |
| Shield Therapeutics INC | $44.60 | 2024 | |
| Idorsia Pharmaceuticals US INC | $33.96 | 2023 | Quviviq |
| Horizon Therapeutics Plc | $33.61 | 2020 | |
| Baxter Healthcare | $31.87 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Edwards Lifesciences Corporation | $31.82 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Lundbeck LLC | $20.09 | 2021 | |
| Nevro Corp. | $19.77 | 2022 | |
| Gilead Sciences, INC. | $18.91 | 2020 | |
| Hologic Sales and Service, LLC | $17.09 | 2024 | Thinprep 2000 Processor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aneta Stirling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.